A Clinical Study of HRS-6209 in Combination With Letrozole in Patients With Breast Cancer
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with letrozole in breast cancer patients, and preliminarily observe its anti-tumor efficacy.